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Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 
3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal sur- 
gery. Radiological studies performed in 19 patients before and at the end of this treatment 
period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumor size was 
observed, and in 3 cases an important shrinkage was documented. At surgery, the adenoma- .: 
tous tissue appeared softer than in nonpretreated patients, facilitating the operation. Patho- 
logical examination revealed widening of perivascular spaces with accumulation of fibrous 
tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologi- :; 
tally pronounced cell involution as observed in prolactin-producing adenomas treated with 
dopamine agonists. No significant difference in frequency or extent of cellular changes was 9 
noted between the two groups. These morphological findings seem to be more consistent 
with a functional inhibition of growth hormone release than with cellular alterations induced 
by octreotide. Endocr Pathol 2" 123-131, 1991, 
9 L 
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Although natural somatostatin strongly inhib- 
its growth hormone (GH) secretion, it could 
not be used successfully in the treatment of 
acromegaly due to its short half-life and 
because of the rebound secretion of GH after 
cessation of the infusion [6]. Recently, anew 
somatostatin a alog, octreotide (Sandostatin, 
Sandoz Ltd., Basel, Switzerland), with a 
marked and prolonged inhibitory effect on 
GH secretion, became available for clinical 
use [5, 13, 15]. In this article, we report data 
recorded from 24 acromegalic patients treated 
with octreotide before transsphenoidal sur- 
gery. Radiological evolution and appearance 
of the adenoma at surgery are reviewed. 
Special attention isgiven to possible morpho- 
logical changes induced by octreotide. 
Mater ia ls  and  Methods  
This series includes 24 acromegalic patients 
(13 men and 11 women, aged 28-63 years). 
Diagnosis of acromegaly was made clinically 
and was confirmed biochemically by elevated 
serum GH and plasma insulinlike growth 
factor I (IGF-I) concentrations and radiologi- 
cally by demonstration f a pituitary tumor by 
computed tomography (CT) scanning or 
magnetic resonance imaging (MRI). Perti- 
nent clinical data are reported in Table 1. 
Octreotide was given at a constant dose 
of 3 x t00 Ixg/day subcutaneously for3 to 6 
weeks before transsphenoidal surgery in 12 
patients (group I, cases 1-12). Twelve pa- 
tients (group II, cases 13-24) were treated for 
6 months before surgery. In this group, the 
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Table 1. Clinical, radiological, and surgical data (groups I and 11) 
Previous 
Treatment 
Case Age (yr)/ (Duration or 
No. Sex Year of Treatment) 
Octreotide-Induced 
Grading Size Reduction 
Tumor Tissue 
Diameter (mm) Aspect 
at Surgery at Surgery 
1 63/M B (2 yr) 
2 63/F 0 
3 56/F 0 
4 41/F 0 
5 56/F B (6 mo) 
6 59/F 0 
7 35/F 0 
8 43/M B (2 too) 
9 591M 
10 56/M 
11 31/M 0 
R (1976) 
[3 (10 yr) 
0 
12 39/M S (1977) 
B (8 yr) 
13 54/F 0 
14 37/M 0 
15 58/M 0 
16 43/M 0 
17 28/M 0 
18 34/M 0 
19 35/M 0 
20 51/F 0 
21 59/F 0 
22 29/F 0 
23 47/F 0 

































20 Soft, necrotic, 
hemorrhagic 
25 Soft, hemorrhagic 
25 Soft, hemorrhagic 













t6 Soft with hard peel 
23 Firm 
dose ofoctreotide was augmented to 3 x 500 
lag/day when a decrease in therapeutic effect 
was experienced, as expressed by a loss of  
inhibition of GH and IGF-I secretion. The 
last injection was given in each case 4 hours 
before surgery. 
The study was approved by the local 
ethical committee. The purpose of  the study 
was explained to the patients, who gave their 
oral consent. 
Radiological Study 
The pituitary region was evaluated by CT 
scanning using a Siemens Somatom 2N or by 
MRI using a Siemens Magnetom before 
octreotide treatment and after 3 weeks in 
group I and after 6 months in group II. 
Grading and suprasellar extension were as- 
sessed as previously described [11, 22]. The 
largest diameter o f  the cavity was also 
measured after adenomectomy. 
Morphological Study 
For light microscopy, small pieces of  tumor 
tissue were fixed in Bouin's solution, dehy- 
drated in a series o f  graded ethanols, and 
embedded in paraffin. Sections were stained 
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Table 2, Pathological data {group t) 
Light Microscopical Electron Microscopical 
Case No. Findings Findings 
1 Acidophitic adenoma Densely granulated mam- 
Immunopositivity: GH, P ILL  mosomatotroph 
(few cells) Lysosomal accumulation: 
Fibrosis: no mild 
Acidophilic adenoma 
hnmunopositivity: GH 
















Fibrosis: minimal, focal 
Chromophobic adenoma 
Immunopositivity: GH (fo- 
cal), PRL (few ceils) 
Fibrosis: minimal, mainly 
perivascular 
Pituitary adenoma and neu- 
ronal choristoma 
Immunopositivity: GH in 
adenoma 
Immunonegativity: GH in 
choristoma 
Fibrosis: focal, partly 
perivascular 
Chromophobic-acidophilic 
adenoma, with focal hem- 
orrhage 
Immunopositivity: GH, PRL 
(few cells) 
Fibrosis: focal, slightly 
perivaseular 
Perivascutar fibrosis: mild 
Endocrine amyloid 




Perivascular fibrosis: mild to 
moderate 
Very densely granulated GH 
cell adenoma, consisting 
of small cells 
Lysosomal accumtflation: o 
Widening of perivascular 
space 
Very densely granulated GH 
cell adenoma 
Lysosomal accumulation: o 
Widening of perivascular 
space 
Densely granulated GH cell 
adenoma 
Widening of perivascular 
space 




Perivascular fibrosis: mild to 
moderate 





Sparsely granulated GH cell 
adenoma 
Lysosomal ccumulation: o 
Perivascular fibrosis: mild to 
moderate 
Sparsely granulated GH cell 
adenoma 
Lysosomal accumulation: o 
Perivascular fibrosis: mild to 
moderate 
Endocrine amyloid 
with hematoxylin-eosin to establish istolog- 
ical diagnosis. 
For immnnocytochemistry, he PAP tech- 
nique was used [20]. Paraffin sections of 4- to 
6-1~m thickness were immunostained for 
GH, prolactin (PP, L), luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), 
thyroid-stimulating hormone (TSH), and 
adrenocorticotropic hormone (ACTH). Dilu- 
tion of primary antibodies varied from 100 to 
640; duration of exposure to the primary 
antibody was 30 minutes. Negative controls 
were performed by incubating the sections 
with the same dilutions of normal rabbit 
serum as were employed for the correspond- 
ing specific antiserum. 
For electron microscopy, small parts of 
tumor tissue were fixed in 4% glutaraldehyde, 
osmicated, dehydrated, and embedded in 
Epon. Ultrathin sections were stained with 
uranyl acetate and lead citrate and investigated 
with a Philips 410-LS electron microscope. 
Results 
In group I, octreotide treatment resulted in 
clinical improvement and a marked reduction 
of serum GH and plasma IGF-I concentra- 
tions, except ill 1 case (case 12). In group II, 
tile initial inhibition of GH and IGF-I 
secretion with 3 x 100 lxg octreotide was 
only retained in 3 cases (13, 15, 16), whereas 
in 4 cases (18, 20, 22, 23) the same therapeutic 
effect was retrieved by increasing the dose. In 
5 cases (14, 17, 19, 21, 24), the increase of the 
octreotide dose to 3 • 500 Ixg could not 
correct the progressive hormonal deteriora- 
tion but still maintained GH and IGF-I levels 
below" pretreatment values. 
Radiological Data 
In group I, no change in tumor size was 
observed in 6 cases after 3 weeks of treatment 
(see Table 1). In 5 cases, a slight reduction 
could be seen, and in 1 case marked shrinkage 
was observed. In group II, no changes were 
observed after 6 months of treatment in 2 
cases, whereas 3 tumors showed a slight 
regression and 2 others were markedly 
smaller. 
Surgical Data 
In group I, the adenomatous tissue appeared 
soft or hemorrhagic in 9 cases (see Table 1). 
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Table 2. (continued) 
10 Acidophilic adenoma, with 
nuclear pleomorphism 





Immunopositivity: GH (fo- 
cal) 
Fibrosis: focal, perivascular 
12 Fibrous tissue trapping afew 
small adenoma cells 
Immunoposidvity: GH Ob- 
cal) 
Fibrosis: massive 




PerivascuJar fibrosis: moder- 
ate 




Densely and sparsely granu- 
lated adenoma cells 
Lysosomal ccumulation: o 
Endocrine amyloid 
GH = growth ormone; PRL = prolactin; LH = luteinizing hormone. 
In 2 cases it was firm and in 1 case fibrotic. In 
the latter case (12) surgical excision could not 
be achieved completely. In group II, the 
adenoma had a soft consistency in 10 cases, 
was liquid in 1 case, and was firm in another 
case. 
Morphological Data 
The data on cases 9 and 12 should be 
interpreted with care, since these patients 
formerly underwent pituitary radiotherapy or
surgery, which could modify the morpholog- 
ical features of the adenoma. Five patients 
received bromocriptine, but it is improbable 
that the morphological changes were induced 
by this treatment, since it was stopped at least 
2 months prior to the octreotide administra- 
tion. 
By light microscopy on hematoxylin- 
eosin-stained slides, the tumors of group I 
were found to be partly acidophilie and partly 
chromophobic adenomas, exhibiting adiffuse 
pattern with some variation in cellularity, 
slight to moderate cellular and nuclear 
pleomorphism, and occasional mitotic figures 
Table 2). With the exception of I case (9) in 
which acum hemorrhagic infarction was 
evident, the adenoma cells showed neither 
necrosis nor damage; the architecture was 
preserved. The capillaries howed no abnor- 
malities; no capillary occlusion, thrombosis, 
or endothelial cell injury was identified. In 5 
cases, minimal or slight perivascular fibrosis 
was noted with widening of perivascular 
spaces, and in 1 case (12) the fibrosis was 
massive. No inflammatory infiltration was 
evident. In I case (8), the adenoma cells were 
interspersed with nerve fibers and large cells 
possessing long cytoplasmic processes and a 
granular cytoplasm resembt}ng nerve cells. 
Neural tissue was revealed in one area 
adjacent m the adenoma. This lesion associ- 
ated with the somatotroph adenoma was 
regarded as representing an adenohypophy- 
seal neuronal choristoma similar to those 
described elsewhere [1, 18]. No striking 
differences were found in group II (Table 3). 
One adenoma showed signs of necrosis (case 
22). Five adenomas howed mild, mainly 
perivascular fibrosis. 
By immunocytochemistry, he adenoma 
cells showed varying degrees ofpositivity for 
GH. Immunoreactivity varied from case to 
case and even from area to area within the 
same tumor. The number of adenoma cells 
showing GH immunoreactivity was not 
counted. Based on nonquantitative evalua- 
tion, adenoma cells with GH immunostain- 
ing were regarded as being between 10 and 
90% of the total population in the various 
tumors. In 5 tumors from group I and 1 
tumor from group II, scattered cells (tess than 
10% of the cell population) yielded PRL 
immunoreactivity. The PRL immunoreactiv- 
it,/was more pronounced in one adenoma of 
group II. Immunostainings for LH, FSH, 
TSH, and ACTH were negative in all 
adenomas. 
By electron microscopy, the tumors of 
group I showed the characteristic features of 
somatotroph adenomas (see Table 2). In 7 
cases the adenomas were densely granulated, 
in 4 adenomas the secretory granules were 
sparse, and in 1 case (12) the tumor was 
composed of both densely and sparsely 
granulated cells. Eleven tumors consisted of 
cells exhibiting the ultrastructural features of 
somatotrophs, whereas 1 tumor (case 1) was 
composed ofmammosomatotrophs. In I case 
(8) in which the adenoma was interspersed 
with nerve cells, as seen by histology, the 
neural components were not recognized in 
the available electron microscopical speci- 
mens. In the case with acute infarction (case 
9), the adenoma cells showed signs of 
advanced necrosis with nuclear pyknosis, 
clumping ofchromatin, chromatotysis, multi- 
focal disruption of the nuclear membrane, 
vesiculation of the endoplasmic reticulum, 
and marked dilation of the Golgi complex. 
The mitochondria were swollen and had lost 
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Table 3. Pathological data {group 11) 
Light Microscopical Electron Microscopical 
Case No. Findings Findings 
13 Strongly acidophilic ade- Very densely granulated GH 
noma with nuclear and cell adenoma, with large 
cellular pleomorphism secretory granules 
Immunopositivity: GH Perivascular fibrosis: no 
Fibrosis: no 
















Immunopositiviw: GH, PRL 
(occasional cells) 
Fibrosis: slight, focal 




Very cellular, strongly acido- 
philic adenoma 
hnmuuopositivity: GH 












Densely granulated ade- 
noma, with features (nu- 
clear morphology', fibrous 
bodies) of sparsely granu- 
lated GH cell adenoma 
Lysosomal accumulation: o 
Densely granulated GH cell 
adenoma 
Sparsely granulated GH cell 
adenoma consisting of 
small cells with fibrous 
bodies 
Perivascular fibrosis: moder- 
ate 
Sparsely granulated GH cell 
adenoma, with fibrous 
bodies 
Lysosomal accumulation: o 
Very densely granulated Girl 
cell adenoma, consisting 
ofve W small cells with 
large secretory granules 
Widening of perivascular 
space 
Perivascular fibrosis: moder- 
ate 
Partly densely, partly 
sparsely granulated GH 
celt adenoma with numer- 
ous fibrous bodies 
Lysosomal accumulation: o 
Endocrine amyloid 
Sparsely granulated GH cell 
adenoma, with minor 
densely granulated com- 
ponent 
Endocrine amyloid 
Very densely granulated GH 




Widening of perivascular 
space 
Endocrine amyloid 
their internal compartments and, in some 
places, cell membranes were discontinuous. 
No cell damage was identified in the remain- 
ing 11 tumors. The nuclei and cell mem- 
branes appeared to be normal. In 10 tumors, 
cell size and nuclear size did not seem to 
differ considerably from control cases, whereas 
in 2 cases (3, 12), cell and nuclear sizes 
appeared to be decreased. The nuclei had 
normal features. The endoptasmic reticulum 
membranes were conspicuous and well- 
preserved. The Golgi complexes were promi- 
nent and consisted of sacculi and sacs 
containing immature secretory granules. The 
fibrous bodies, a characteristic feature of 
sparsely granulated GH cell adenomas [12] 
were noticeable without differing in size, 
number, and ultrastructural ppearance from 
those seen in untreated somatotroph ade- 
nomas. The mitochondria were ovoid or 
rod-shaped and had tubular cristae and a 
moderately electron-dense matrix~ The size 
and number of secretory granules eemed to 
be slightly larger and more numerous in 2 
cases of densely granulated tumors (3, 4), 
whereas they were within the normal range in 
the rest of the adenomas. As considerable 
variation existed from one tumor to the other 
and even between different areas of the same 
tumor, and because no morphometric analy- 
sis has been performed, definite conclusions 
could not be drawn as to whether the size and 
number of secretory granules had changed 
during treatment with octreotide. The lyso- 
somes in 6 cases eemed to be unusually large 
and coalesced, containing lipid droplets and 
secretory granules. Crinophagy (i.e., the 
uptake of secretory granules into lysosomes) 
was more pronounced in the adenomas of 
patients treated with octreotide compared to 
those with no octreotide medication before 
surgery (Fig. 1). In 11 somatotroph ade- 
nomas, no exowtosis was observed, whereas 
in the mammosomatotroph adenoma, extru- 
sion of secretory granules was common. The 
capillaries, in general, appeared to be normal 
and patent; no platelet aggregation, thrombo- 
sis, or vascular occlusions were seen. The 
endothelial cells showed no major alterations. 
In 3 cases, the perivascular space was wider 
than in the untreated cases; accumulation of 
fibroblasts and collagen fiber deposits were 
observed. This perivascutar fibrosis was slight 
to moderate in 8 tumors and absent in 3 
tumors. No interstitial fibrosis was found. It 
is noteworthy that 4 adenomas contained 
endocrine amyloid. 
The morphological features by electron 
microscopy of the adenomas from group 1I 
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Table 3, Icontinued) 
22 Cellular, chromophobic- Sparsely granulated GH cell 
acidophilic adenoma, with adenoma 
signs of early necrosis Lysosomal ccumulation: o 
Immunopositivity: GH, PRL Widening ofperivascular 
(many cells) space 
Fibrosis: minimal, perivas- 
cutar 
23 Very cellular, slightly acido- Sparsely granulated GH cell 
philic adenoma adenoma, consisting of 
Immunopositivity: GH small cells 
Fibrosis: no Perivascular fibrosis: no 
24 Acidophilic adenoma Densely granulated GH cell 
Immunopositivity: GH, adenoma 
FSH (occasional cells) Lysosomal ccumulation: o 
Fibrosis: mild, focal, perivas- 
cular 
GH = growth hormone; PRL = protactin; FSH = tk)tlicle-stimutating hormone. 
(see Table 3) were not significantly different 
from those noted in group I. Six densely 
granulated adenomas were observed. In 5 
adenomas, the secretory granules were sparse 
and, in 1 case (19), the tumor was composed 
of both densely and sparsely granulated cells. 
One densely granulated GH cell adenoma 
(case 14) consisted of cells that were often 
spherule-shaped and possessed eccentric, 
crescent-shaped nucleus and fibrous bodies 
(Fig. 2). These findings suggest hat this 
tumor represented an originally sparsely 
granulated GH cell adenoma nd accumula- 
tion of secretory granules was the result of 
Figure 1. Mammosomatotroph adenoma os a patient (case 1} treated with oc- 
treotide for 3 weeks. The adenoma cells contain large, irregular secretory gran- 
ules, some of which have a mottled appearance (arrowhead). Note crinophagy 
(arrowsJ. {x 10,500.) 
somatostatin analog treatment. Cell size 
seemed to be decreased in 2 cases (16, 18). In 
3 of the densely granulated adenomas (cases 
13, 18, 21), unusually numerous and large 
secretory granules were observed. Striking 
accumulation of tysosomes was noted in 1 
case (21). Endocrine amyloid was present in 3 
adenomas (Fig. 3). 
Discussion 
The suppressive activity ofoctreotide on GH 
secretion and its therapeutic value in the 
management of acromegaly are now well 
established [7, 8, 14]. This study was initiated 
to assess the effect of octreotide on volume, 
appearance, and morphological features of 
GH cell adenomas. Shrinkage of GH cell 
adenomas would make octreotide a useful 
drug to prepare patients for surgery [17]. In 
our series, involution was obtained in t 1 of 19 
cases, but it was only significant in 3 cases. 
Modest reduction in tumor size in 3 of 6 
patients has been reported by Barnard and 
colleagues [4], whereas Ducasse and associ- 
ates [9] described major regression in 1 
patient treated with an infusion ofoctreotide. 
Barkan and co-workers [2] observed signifi- 
cant reduction of the tumor volume in 9 of 15 
acromegalic patients. 
The soft consistency ofthe adenomatous 
tissue found at surgery makes the operation 
easier. This softening effect of octreotide was 
recorded in 19 of our cases and was also 
observed by Spinas and colleagues [19] in 5 
cases. However, larger series are required to 
reach definitive conclusions regarding the 
influence of octreotide on tissue softening, 
shrinkage of the adenoma, and potential 
benefits of these effects. 
The morphological response of somato- 
troph adenomas to octreotide was not uni- 
form and not marked, despite the fact that the 
drug caused clinical improvement and sub- 
stantial decrease in serum GH levels in 
acromegalic patients. Lysosomes were large 
and numerous in several cells, and crino- 
phagy was observed, suggesting that hormone 
release was suppressed and the retained 
secretory products ofadenomatous cells were 
intracellularly degraded by lysosomes. Some 
adenomatous cells appeared to be smaller 
than those of untreated somatotroph ade- 
nomas and, in several tumors, varying degrees 
Acromegaly and Octreotide 129 
Figure 2. Growth hormone (GH) cell adenoma of a patient (case 14) treated 
with octreotide for 6 months. The adenoma cells are densely granulated, but oth- 
erwise they have ultrastructural characteristics of a sparsely granulated GH cell 
adenoma. (• 6,000.) 
ofperivascular fibrosis was noticeable. Some 
tumors removed from octreotide-treated pa-
tients were, however, morphologically indis- 
tinguishable from those not exposed to 
octreotide. Furthermore, no morphological 
difference could be evidenced between ade- 
Figure 3. Foci of endocrine amyloid (asterisk) in the densely granulated growth 
hormone cell adenoma of a patient (case 21 ) treated with octreotide for 6 
months. (x 11,800,) 
nomas treated ~br 3 weeks and those treated 
for 6 months. Also, no important difference 
could be detected between adenomas of 
patients presenting with an escape to the 
long-term treatment and those from patients 
who remained responsive. In the present 
series, with the exception of 2 adenomas with 
large areas of hemorrhagic necrosis, no cell 
necrosis, endothelial injury', platelet aggrega- 
tion, vascular damage, or thrombosis was 
noted, indicating that octreotide had no direct 
cytotoxic or vasotoxic effects. The vascular 
change in the 2 exceptional cases was 
interpreted as an incidental finding, since 
hemorrhages and loci of necrosis also occur 
in tumors not exposed to octreotide [12]. 
Our morphological results are in agree- 
ment with the literature. Landolt and Oster- 
walder [16] found amyloid deposits and 
perivascular fibrosis but no consistent ultra- 
structural alterations in the secretory appara- 
tus of adenoma cells. George and colleagues 
[10] investigated the somatotroph adenoma 
of a 36-year-old acromegalic woman treated 
for 10 days with octreotide. These authors 
noted an abundance of lysosomes with 
crinophagy and broadening of the perivascu- 
tar space with slight fibrosis around the 
capillaries. Compared to 10 somatotroph 
adenomas not exposed to octreotide, the 
adenoma cells in the octreotide-treated pa-
tient appeared to be smaller and contained 
smaller nuclei as well as cytoplasm, and 
lysosomes occupied a larger area of the 
cytoplasmic volume. The nuclear-cytoplas- 
mic ratio, cytoplasmic volume densities of 
endoplasmic reticulum, Golgi apparatus, mi- 
tochondria, and secretory granule diameters 
did not differ significantly from the control 
values. Barkan and co-workers [3] observed 
perivascular fibrosis and a reduction of both 
cytoplasmic and nuclear areas. These authors 
also reported 2 densely granulated adenomas 
with features of initially sparsely granulated 
adenomas, resembling the morphological 
appearance of i case in our series. 
All these results are consistent with 
functional inhibition of GH release. Dopa- 
mine agonists, such as bromocriptine, cause 
reversible shrinkage of PRL-secreting pitu- 
itary adenomas associated with morphologi- 
cally pronounced cell involution [21]. The 
changes are striking and are characterized by a 
substantial decrease in cell size and cytoplas- 
mic and nuclear area, an increase in the 
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nuclear-cytoplasmic ratio, and a reduction in 
cytoplasmic volume densities ofendoplasmic 
reticulum membranes and Golgi apparatus. 
These changes are not apparent in GH-  
secreting pituitary adenomas exposed to 
octreotide. Thus, in tumors removed from 
octreotide-treated patients, a discrepancy ex- 
ists between functional inhibition and mor- 
phological findings. 
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